Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.62 |
| ▸ | SLC5A2 | P31639 | 16/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27085180 | 0.90 | SLC5A2 (0.66) | MTNR1AMTNR1BSLC5A2SLC5A1 | |
| SCHEMBL27084926 | 0.85 | MTNR1A (0.62) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL30630312 | 0.85 | MTNR1A (0.62) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL27084669 | 0.82 | HTR6 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL27085121 | 0.80 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL27084728 | 0.80 | HTR2A (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL27084686 | 0.80 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL27085009 | 0.80 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL27085022 | 0.80 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL29112608 | 0.79 | SLC5A2 (0.52) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | MTNR1A 40/4885MTNR1B 89/4885SLC5A2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.